| Los Angeles Reins In Its Pot Shops City officials hope a new get-tough policy will finally let them gain control over the 600 or so marijuana dispensaries that have sprung up over the past few years. But many dispensaries don't want to go quietly. online.wsj.com |
Hedge Fund MHR Receives More Convertible Notes From Emisphere Technologies Market Folly submits:MHR Fund Management run by Mark Rachesky recently filed a Form 4 with the SEC in regards to Emisphere Technologies (EMIS). Per the filing, Rachesky's firm received convertible notes on EMIS for reasons we'll discuss below. We see that MHR acquired $1,272,753 worth of convertibles with an exercise price of $3.78 and an exercise date of September 26th, 2012. These convertibles in aggregate represent 336,705 shares of common stock in Emisphere Technologies.This is not the first time MHR has acquired EMIS convertibles either. Rachesky's firm has owned 11% Senior Secured Convertible Notes since May 16th, 2006. These convertibles have interestComplete Story » seekingalpha.com |
Life Technologies Q2 2010 Earnings Call Transcript Life Technologies (LIFE)Q2 2010 Earnings CallJuly 29, 2010 8:30 am ETComplete Story » seekingalpha.com |
Blood-Thinning Drug Gets Nod An FDA panel recommended that the FDA approve Boehringer's blood-thinning drug Pradaxa, a move likely to place the company as the first to get a new type of drug on the U.S. market to prevent strokes in patients with irregular heart rhythms. online.wsj.com |
Alexza's CRL Offers Long Term Investment Opportunity Rockford Coscia submits: The FDA showed it was playing hardball this October by delivering two completes response letters (CRLs) last Friday – one to Jazz Pharmaceuticals (JAZZ) and the other to Alexza Pharmaceuticals (ALXA). While the Jazz CRL was generally expected, Alexza Pharmaceuticals was widely expected to gain approval on first pass - RBC even stated odds of approval as high as 65%. As a result, the share price took a 55% haircut in the first day of trading after its rejection and continues downward today. While making a play on this stock before Alexza reports its discussions with the FDA about the CRL is a risky proposition, those that buy at these low prices stand to be handsomely rewarded when the uncertainty is resolved. The issues brought up in the CRL according to the conference call held this morning appear to be based on the following four points.Complete Story » seekingalpha.com |